

Supplemental Table 1 Brief chronology of key clinical events in this case

Time before and after CAR T cell therapy	Date	Key events
-8.5 months	09/14/2018	Diagnosis of DLBCL, GCB
-8 months to -3 months	09/19/2018 to 01/22/2019	6 cycles of <i>R-CHOP</i> (response evaluation: PD)
-2.5 months	02/19/2019	1 cycle of <i>R-ESHAP</i> (response evaluation: PD)
-3 weeks	03/15/2019	1 cycle of <i>ICE</i>
-9 days to -1 day	04/25/2019 to 05/01/2019	Lymphocytes collection and myeloablative chemotherapy regimen (<i>BEAM</i>)
0 day	05/02/2019	<i>ASCT</i>
+6 day	05/08/2019	<i>Murine anti-CD22 CAR T cell therapy</i> (2.77 x 10 ⁶ cells/kg)
+7 day	05/09/2019	<i>Murine anti-CD19 CAR T cell therapy</i> (2.50 x 10 ⁶ cells/kg)
+1.5 month	06/27/2019	Response evaluation by CT : SD
+2 months	07/12/2019	Response evaluation by PET/CT : PD
+2.5 months to +3 months	07/19/2019 to 08/11/2019	<i>Sintilimab Injection</i> (an anti PD-1 antibody) plus novel immunotherapeutic drugs (<i>rituximab, chidamide, bortezomib and dexamethasone</i>)
+5 months	10/02/2019 to 10/06/2019	Lymphodepleting chemotherapy regimen (<i>FC</i>) and <i>human anti-BCMA CAR T cell therapy</i>
+6 months	11/05/2019	Response evaluation by PET/CT : PD